OverviewChartNewsTraderScreen

BNP Paribas Aktienanleihe SNW 27..../  DE000PC1XVS6  /

EUWAX
5/13/2024  9:06:00 AM Chg.+0.52 Bid2:42:59 PM Ask2:42:59 PM Underlying Strike price Expiration date Option type
100.44EUR +0.52% 100.57
Bid Size: 100,000		 100.67
Ask Size: 100,000		 SANOFI SA INHABER ... 90.00 EUR 6/27/2024 Call
GlobeNewswire 1:00 PM Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 12:00 PM Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
TeleTrader 9:01 AM Europe mixed at open as CPI prints loom
GlobeNewswire 7:00 AM Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 5/10 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 5/10 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 5/10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 5/9 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 5/9 Europe opens mixed with BoE in focus
GlobeNewswire 5/8 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/7 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 5/2 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 5/2 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 4/30 Press Release: Annual General Meeting of April 30, 2024
TeleTrader 4/25 Europe opens mostly down after corporate earnings
TeleTrader 4/25 Europe down in premarket as financial results pour in
TeleTrader 4/25 Sanofi books net sales of €10.5B in Q1, up 2.4%
GlobeNewswire 4/25 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire 4/23 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire 4/17 IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire 4/17 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire 4/16 2024 DTA Summit Agenda is LIVE!!
GlobeNewswire 4/10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 4/9 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire 3/29 Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update